Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Zevra Therapeutics (NASDAQ: ZVRA) was one of the healthier companies on the stock exchange on Tuesday. Investors eagerly piled into its shares following the commercial-stage biotech's latest earnings release, leaving Zevra with a slightly over 21% gain that day. Zevra's final set of 2025 earnings was released just after market close Monday, revealing that the company's net revenue was slightly over $34 million in the fourth quarter. That was 44% higher than the same period of 2024. Better, the company flipped to a net profit under generally accepted accounting principles (GAAP) of $12.2 million ($0.19) per share, from the year-ago loss of $35.7 million. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool